Literature DB >> 17694294

[Establishing a protein signature from prostate tissue biopsies].

U Zimmermann1, R Ummanni, H Junker, S Venz, S Teller, J Giebel, R Walther.   

Abstract

The prostate-specific antigen test (PSA) has been a major factor contributing to a better management of prostate cancer. The low specificity limits its use in diagnosis especially in early detection of prostate cancer. Multiply expressed proteins need to be identified to establish a disease-specific protein signature that distinguishes between cancerous and noncancerous tissue. The first aim of our study is to identify differentially expressed proteins in both tissues using two-dimensional gel electrophoresis and subsequent mass spectrometry. We elucidated whether prostate biopsies are useful. First results have shown a different protein expression pattern in cancerous and noncancerous tissue. PCR revealed an increasing amount of mRNA for some upregulated proteins. We conclude that biopsies are useful material to establish protein expression patterns.

Entities:  

Mesh:

Year:  2007        PMID: 17694294     DOI: 10.1007/s00120-007-1510-7

Source DB:  PubMed          Journal:  Urologe A        ISSN: 0340-2592            Impact factor:   0.639


  3 in total

1.  Preoperative serum prostate specific antigen levels between 2 and 22 ng./ml. correlate poorly with post-radical prostatectomy cancer morphology: prostate specific antigen cure rates appear constant between 2 and 9 ng./ml.

Authors:  Thomas A Stamey; Iain M Johnstone; John E McNeal; Arthur Y Lu; Cheryl M Yemoto
Journal:  J Urol       Date:  2002-01       Impact factor: 7.450

2.  PSA, PSA density, PSA density of transition zone, free/total PSA ratio, and PSA velocity for early detection of prostate cancer in men with serum PSA 2.5 to 4.0 ng/mL.

Authors:  B Djavan; A Zlotta; C Kratzik; M Remzi; C Seitz; C C Schulman; M Marberger
Journal:  Urology       Date:  1999-09       Impact factor: 2.649

Review 3.  The role of PSA and percent free PSA for staging and prognosis prediction in clinically localized prostate cancer.

Authors:  J Pannek; A W Partin
Journal:  Semin Urol Oncol       Date:  1998-08
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.